Coati, Irene
Lotz, Gábor
Fanelli, Giuseppe Nicolò
Brignola, Stefano
Lanza, Cristiano
Cappellesso, Rocco
Pellino, Antonio
Pucciarelli, Salvatore
Spolverato, Gaya
Guzzardo, Vincenza
Munari, Giada
Zaninotto, Giovanni
Scarpa, Marco
Mastracci, Luca
Farinati, Fabio
Realdon, Stefano
Pilati, Pierluigi
Lonardi, Sara
Valeri, Nicola
Rugge, Massimo
Kiss, Andras
Loupakis, Fotios http://orcid.org/0000-0001-9651-0395
Fassan, Matteo
Funding for this research was provided by:
Università degli Studi di Padova (DOR)
Article History
Received: 2 May 2019
Revised: 3 June 2019
Accepted: 5 June 2019
First Online: 25 June 2019
Competing interests
: F.L. had roles as consultant or advisor for Roche, Bayer, Amgen and Genentech. S.L. had roles as consultant or advisor for Amgen, Bayer, Merck Serono and Lilly. She received research funding from Amgen and Merck Serono and is part of the speaker’s bureau of Lilly and BMS. N.V. received honoraria for lectures from Merck Serono, Bayer, Eli Lilly and Pfizer. The other authors declare that they have no conflict of interest.
: Only material that was not required for diagnosis was used and all patients signed an informed consent approved by the University Hospital of Padua Review Board which allows researchers to use excess material for research purposes. The study was approved by the local Ethic Committee.
: This work was partly supported by the grants from the Italian Association for Cancer Research (AIRC Regional grant 2008 N. 6421) and DOR grant from Padua University. The funding agencies had no role in the design and performance of the study.
: The data sets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).